{"id":42603,"date":"2023-04-30T17:49:47","date_gmt":"2023-04-30T21:49:47","guid":{"rendered":"https:\/\/www.sisinternational.com\/?page_id=42603"},"modified":"2026-05-05T17:01:22","modified_gmt":"2026-05-05T21:01:22","slug":"etude-de-marche-sur-le-diagnostic-clinique","status":"publish","type":"page","link":"https:\/\/www.sisinternational.com\/fr\/solutions\/etudes-de-marche-sur-les-biotechnologies-et-les-produits-pharmaceutiques-en-matiere-de-soins-de-sante-medicaux\/etude-de-marche-sur-le-diagnostic-clinique\/","title":{"rendered":"Clinical Diagnostics Market Research | SIS International"},"content":{"rendered":"
\n

\u00c9tude de march\u00e9 sur le diagnostic clinique<\/a><\/h1>\n
\"\u00c9tudes<\/figure>\n<\/p>\n

Clinical Diagnostics identifies the presence or absence of a disease or medical condition. Medical professionals do Clinical Diagnostics through various tests and procedures. The diagnostic process involves a series of steps. For example, the process may include medical history, physical examination, and laboratory tests. They may also consist of imaging studies and other diagnostic<\/a> procedures. Medical professionals use all these methods to make a definitive diagnosis. Or, they may use them to rule out potential conditions.<\/p>\n

Une autre fonction des diagnostics cliniques est d'identifier et de g\u00e9rer divers probl\u00e8mes de sant\u00e9. Ils attrapent des maladies courantes (par exemple la grippe). Ils identifient \u00e9galement des maladies plus complexes et chroniques comme le cancer et le diab\u00e8te. De plus, les concepteurs de tests et de proc\u00e9dures misent beaucoup sur leurs produits. Ils se sont assur\u00e9s de pouvoir fournir des r\u00e9sultats pr\u00e9cis et fiables. Ces r\u00e9sultats devraient guider les d\u00e9cisions de traitement et am\u00e9liorer les r\u00e9sultats pour les patients.<\/p>\n

Quelques exemples de tests et de proc\u00e9dures de diagnostic clinique comprennent les analyses de sang et d'urine. Les \u00e9tudes d'imagerie, comme les radiographies et les IRM, sont \u00e9galement diagnostiques. Il en va de m\u00eame pour les biopsies et les tests g\u00e9n\u00e9tiques. Un autre point cl\u00e9 est que les tests et proc\u00e9dures sp\u00e9cifiques d\u00e9pendent de l\u2019affection suspect\u00e9e. Ils portent \u00e9galement sur les sympt\u00f4mes et les ant\u00e9c\u00e9dents m\u00e9dicaux du patient.<\/p>\n

Pourquoi les diagnostics cliniques sont-ils importants ?<\/h2>\n

Les diagnostics cliniques sont essentiels pour plusieurs raisons, notamment la d\u00e9tection pr\u00e9coce et la pr\u00e9vention. En fait, les diagnostics cliniques permettent la d\u00e9tection pr\u00e9coce des maladies et des probl\u00e8mes de sant\u00e9. Une d\u00e9tection pr\u00e9coce peut aider \u00e0 pr\u00e9venir le d\u00e9veloppement de complications plus graves. En outre, un diagnostic et un traitement pr\u00e9coces sont cruciaux pour le cancer, les maladies cardiovasculaires et le diab\u00e8te. Cela peut am\u00e9liorer les r\u00e9sultats et r\u00e9duire les taux de mortalit\u00e9.<\/p>\n

Les diagnostics cliniques fournissent des informations pr\u00e9cises et fiables sur l'\u00e9tat d'un patient. Ces informations sont essentielles pour prendre des d\u00e9cisions de traitement \u00e9clair\u00e9es. Sans oublier que sans un diagnostic appropri\u00e9, les patients peuvent recevoir un traitement inad\u00e9quat et inappropri\u00e9. Pire encore, le traitement peut \u00eatre nocif, voire mettre la vie en danger.<\/p>\n

Les diagnostics cliniques permettent de surveiller la r\u00e9ponse d'un patient au traitement au fil du temps. Les prestataires de soins de sant\u00e9 peuvent utiliser ces informations pour ajuster les plans de traitement. Gr\u00e2ce \u00e0 cela, ils peuvent \u00e9galement garantir que les patients re\u00e7oivent les meilleurs soins possibles.<\/p>\n

Les diagnostics cliniques jouent un r\u00f4le essentiel dans la recherche et le d\u00e9veloppement m\u00e9dical. Les professionnels de la sant\u00e9 les utilisent pour tester de nouvelles th\u00e9rapies et m\u00e9dicaments. Ils peuvent \u00e9galement identifier de nouveaux biomarqueurs et cibles pour le traitement des maladies.<\/p>\n

Pour clarifier, les diagnostics cliniques sont essentiels pour am\u00e9liorer les r\u00e9sultats pour les patients et faire progresser les connaissances m\u00e9dicales. Ils permettent un diagnostic pr\u00e9cis de diverses maladies et affections. Ils permettent \u00e9galement un traitement efficace, conduisant \u00e0 de meilleurs r\u00e9sultats pour la sant\u00e9 des patients.<\/p>\n<\/div>\n

Clinical Diagnostics \u00c9tude de march\u00e9<\/a>: How Leaders Build Defensible Launch Strategy<\/h1>\n

Clinical diagnostics market research now decides which assays reach reimbursement and which stall in pilot accounts. The diagnostics buyer is no longer a single pathologist. It is a procurement committee balancing reagent cost, instrument footprint, LIS integration, and payer coverage decisions. Winning teams treat that complexity as an addressable variable, not a barrier.<\/p>\n

The opportunity is significant. Molecular diagnostics, companion diagnostics (CDx), point-of-care (POC) platforms, and laboratory-developed tests (LDTs) are converging into a single competitive arena. The firms gaining share are the ones running disciplined primary research against the actual decision unit: lab directors, KOL pathologists, payer medical directors, and health system supply chain leads.<\/p>\n

What Sophisticated Clinical Diagnostics Market Research Now Measures<\/h2>\n

The conventional approach maps physician preference and stops there. The better approach maps the full reimbursement-to-utilization chain. That means quantifying CPT code coverage decisions, PAMA-driven price compression on the Clinical Laboratory Fee Schedule, and the gating effect of MolDX local coverage determinations on assay adoption.<\/p>\n

Three measurement layers separate strong diagnostics research from generic physician surveys. First, payer value story testing against medical policy criteria. Second, lab director willingness-to-validate scoring, which predicts adoption faster than physician intent. Third, KOL mapping that distinguishes guideline authors from prescribing volume leaders. The two rarely overlap.<\/p>\n

SIS International’s structured expert interviews with pathologists, oncologists, and reproductive health specialists in tier-one and tier-two Indian metros surfaced a pattern most secondary reports miss: in molecular diagnostics, ordering behavior follows turnaround time and send-out logistics more than analytical sensitivity, once a minimum performance bar is met.<\/span> That insight reframes commercial priorities for any oncology or NIPT entrant.<\/p>\n

Why Companion Diagnostics Demand a Different Research Design<\/h2>\n

Companion diagnostics sit inside a pharma launch. The research question is not “will physicians order this test.” It is “will the test keep pace with therapy uptake across reference labs, hospital labs, and decentralized POC settings.” Roche, Illumina, and Thermo Fisher build CDx commercial strategy on parallel-track studies that interview pharma alliance managers and lab medical directors in the same wave.<\/p>\n

Real-world evidence (RWE) generation runs alongside. Payers increasingly demand outcomes data tied to test-directed therapy before issuing positive coverage. Research design that ignores this produces a value story the medical policy team will reject in the first review cycle.<\/p>\n

Point-of-Care and Decentralized Testing: A Distinct Decision Unit<\/h2>\n

POC molecular platforms from Cepheid, BioFire, and Abbott shifted procurement authority away from central lab directors toward emergency department leadership, urgent care operators, and retail clinic chains. Each buyer applies different criteria. ED leaders weigh door-to-disposition time. Retail operators weigh CLIA-waived status and cartridge cost per test. Central labs weigh menu breadth and middleware integration.<\/p>\n

Research that treats POC as one segment loses precision. The leading sponsors run segmented quantitative work with separate sample frames per care setting, then triangulate against installed base analytics from GPO contract data.<\/p>\n

Geographic Nuance Drives Forecast Accuracy<\/h2>\n

Diagnostics adoption curves diverge sharply across markets. India’s molecular diagnostics market grows through standalone reference labs and oncology-focused chains. Brazil’s growth concentrates in private hospital networks and SUS tender cycles. Germany’s path runs through statutory health insurance EBM coding decisions. China’s NMPA pathway and volume-based procurement rewrite unit economics on entry.<\/p>\n

Across SIS International Research engagements in Brazilian healthcare, mixed-methodology designs combining hospital procurement interviews with quantitative physician surveys have consistently produced forecast variance under fifteen percent against actual two-year uptake, where single-method secondary forecasts have drifted further.<\/span> The discipline is straightforward: pair installed base reality with stated intent, then weight by reimbursement gating.<\/p>\n

The SIS Diagnostics Decision-Unit Framework<\/h2>\n

For pillar planning, the framework below organizes primary research scope across the four buyers that determine commercial outcome.<\/p>\n

\n\n\n\n\n\n\n\n\n
Decision Unit<\/th>\nPrimary Lever<\/th>\nM\u00e9thode de recherche<\/th>\n<\/tr>\n<\/thead>\n
Lab Director \/ Pathologist<\/td>\nValidation burden, menu fit<\/td>\nB2B expert interviews, willingness-to-validate scoring<\/td>\n<\/tr>\n
Ordering Physician (KOL + community)<\/td>\nClinical utility, guideline alignment<\/td>\nQuantitative survey, conjoint on test attributes<\/td>\n<\/tr>\n
Payer Medical Director<\/td>\nEvidence package, coverage policy<\/td>\nPayer value story testing, RWE gap analysis<\/td>\n<\/tr>\n
Health System Procurement \/ GPO<\/td>\nTotal cost, contract structure<\/td>\nProcurement interviews, TCO modeling<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n

Source: SIS International Research<\/em><\/p>\n

What Separates Launch-Ready Research From Reference-Shelf Research<\/h2>\n

Three signals indicate research that will hold up in a launch readiness review. The sample frame names specific institution types and regions, not “US hospitals.” The instrument tests price points anchored to actual CPT reimbursement, not arbitrary willingness-to-pay scales. The output ties directly to medical affairs, market access, and commercial workstreams with named decisions assigned to each.<\/p>\n

SIS International’s proprietary research in clinical mobility and diagnostics adoption across US and UK hospital systems found that IT integration friction, specifically LIS and EMR middleware compatibility, was the single largest predictor of replacement-cycle losses for incumbent platforms.<\/span> Sponsors who quantified that variable in advance won net-new accounts at materially higher rates.<\/p>\n

Where the Market Is Moving<\/h2>\n

Liquid biopsy, multi-cancer early detection (MCED), AI-enabled digital pathology, and next-generation sequencing menu expansion are reshaping competitive boundaries. Guardant Health, Exact Sciences, GRAIL, and Natera each compete on a different combination of clinical evidence depth, payer coverage breadth, and channel access. Research that benchmarks them on a single axis will mislead the strategy team.<\/p>\n

The forward question for diagnostics leaders is not market size. It is which decision-unit configurations in which geographies will convert evidence into reimbursed volume fastest. Clinical diagnostics market research, designed around that question, becomes a launch asset rather than a deck.<\/p>\n

Key Questions<\/h2>\n
\"\u00c9tudes<\/figure>\n

Senior diagnostics leaders engaging SIS most often ask how to size molecular diagnostics opportunity in emerging markets, how to structure payer evidence for a CDx launch, and how to segment POC buyers by care setting. Each requires a different primary research design and a different sample frame.<\/p>\n

\u00c0 propos de SIS International<\/h2>\n

SIS International<\/a> propose des recherches quantitatives, qualitatives et strat\u00e9giques. Nous fournissons des donn\u00e9es, des outils, des strat\u00e9gies, des rapports et des informations pour la prise de d\u00e9cision. Nous menons \u00e9galement des entretiens, des enqu\u00eates, des groupes de discussion et d\u2019autres m\u00e9thodes et approches d\u2019\u00e9tudes de march\u00e9. Contactez nous<\/a> pour votre prochain projet d'\u00e9tude de march\u00e9.<\/p>\n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n<\/p>\n

\n

Related SIS Resources<\/h3>\n